Call Us Toll Free: 1-800-388-9993

 

A reliable investment strategy: Identify a widely diversified portfolio of high-quality stocks and build up additional holdings at favorable prices.

 

DRIPs can help you do that.

 

Even small investors can follow such a strategy by investing through dividend reinvestment plans (DRIPs). That's because it takes ownership of only a single share of company stock to establish an account. Therefore, there is nothing to stop you from buying companies in a variety of industries.

 

As for buying at favorable prices, dollar-cost averaging virtually assures that you will buy most shares at favorable prices. And DRIPs provide an excellent way to dollar-cost average. These plans allow you to invest cash amounts to buy shares directly from the company. Once you are enrolled in a plan, you can invest amounts of as little as $25 or $50 (or as much as you can afford) to buy shares or fractions of shares. That's different than the traditional way to invest, which is to pay brokerage fees to buy a certain number of shares.

 

 

AstraZeneca PLC (AZN)

Available from the Temper Enrollment Service: Yes


Last Update On: 01/07/2021:

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab) and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. **Taken from Yahoo Finance**

Industry: Pharmaceutical R & D
Minimum Investment: $50.00
Maximum Investment: $10,000/investment
Shares to qualify: 1
Recent Price: 47.73
Investing Fee: $5+12¢/sh.
Fee for Dividends: 5% (to $2.50)+12¢/sh.

Company Information

Your subscription status does not entitle you to access this information. You may review subscription options under the "Subscribe" link on the top menu bar.

You may also sign up for a free guest pass here to view this company's detailed information.

! = Company pays fees

Information is based on an annual survey and updated when company changes become available.

Click for Español

FOR MORE
INFORMATION

And a free copy of The Moneypaper's direct investing brochure, please enter your contact information below.

You will also be signed up to receive our monthly stock special.

You can unsubscribe at any time. We do not share your email with anyone.

By email, you get the Monthly “Stock Special,” where the service fee for enrollment in a great DRIP stock is reduced.

* Required Field.